{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:47:21Z","timestamp":1761511641997},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2001,5,1]],"date-time":"2001-05-01T00:00:00Z","timestamp":988675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6825,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2001,5]]},"DOI":"10.1023\/a:1011140818150","type":"journal-article","created":{"date-parts":[[2002,12,23]],"date-time":"2002-12-23T11:26:45Z","timestamp":1040642805000},"page":"627-631","source":"Crossref","is-referenced-by-count":5,"title":["Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks"],"prefix":"10.1016","volume":"12","author":[{"given":"S.R.","family":"Alberts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Erlichman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.H.","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.A.","family":"Burch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.C.","family":"Pitot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.M.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.J.","family":"Atherton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.H.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1011140818150_bb0010","series-title":"Investigational Anticancer Agents","author":"Parkinson","year":"1996"},{"key":"10.1023\/A:1011140818150_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0305-7372(96)90014-6","article-title":"Clinical, toxicological and pharmacological aspects of gemcitabine","volume":"22","author":"Guchelaar","year":"1996","journal-title":"Cancer Treat Rev"},{"key":"10.1023\/A:1011140818150_bb0020","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/jnci\/91.21.1876","article-title":"Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters","volume":"91","author":"Mackey","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1011140818150_bb0025","series-title":"Cytidine Analogues","author":"Chabner","year":"1996"},{"key":"10.1023\/A:1011140818150_bb0030","first-page":"3","article-title":"Gemcitabine: Metabolism, mechanisms of action, and self-potentiation","volume":"22","author":"Plunkett","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1011140818150_bb0035","first-page":"3","article-title":"Gemcitabine Preclinical pharmacology and mechanisms of action","volume":"23","author":"Plunkett","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1011140818150_bb0040","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","article-title":"A phase I clinical, plasma, and cellular pharmacology study of gemcitabine","volume":"9","author":"Abbruzzese","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011140818150_bb0045","first-page":"567","article-title":"Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine","volume":"38","author":"Heinemann","year":"1990","journal-title":"Mol Pharmacol"},{"key":"10.1023\/A:1011140818150_bb0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00685844","article-title":"Fludarabine- and gemcitabine-induced apoptosis Incorporation of analogs into DNA is a critical event","volume":"36","author":"Huang","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1023\/A:1011140818150_bb0055","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/0006-2952(93)90566-F","article-title":"2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines","volume":"46","author":"Ruiz van Haperen","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.1023\/A:1011140818150_bb0060","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0167-4781(98)00130-4","article-title":"Clinical applications of the camptothecins","volume":"1400","author":"Takimoto","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"10.1023\/A:1011140818150_bb0065","first-page":"21","article-title":"CPT-11: An original spectrum of clinical activity","volume":"23","author":"Rothenberg","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1011140818150_bb0070","first-page":"39","article-title":"Pharmacology of irinotecan","volume":"12","author":"Kuhn","year":"1998","journal-title":"Oncology"},{"key":"10.1023\/A:1011140818150_bb0075","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1126\/science.279.5356.1534","article-title":"A model for the mechanism of human topoisomerase I","volume":"279","author":"Stewart","year":"1998","journal-title":"Science"},{"key":"10.1023\/A:1011140818150_bb0080","first-page":"1","article-title":"Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme","volume":"1400","author":"Pommier","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"10.1023\/A:1011140818150_bb0085","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1749-6632.1996.tb26375.x","article-title":"Mechanism of action of camptothecin","volume":"803","author":"Liu","year":"1996","journal-title":"Ann N Y Acad Sci"},{"key":"10.1023\/A:1011140818150_bb0090","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/jnci\/85.4.271","article-title":"The current status of camptothecin analogues as antitumor agents","volume":"85","author":"Slichenmyer","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1011140818150_bb0095","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/jnci\/86.11.836","article-title":"Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials","volume":"86","author":"Tanizawa","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1011140818150_bb0100","first-page":"S7","article-title":"In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model","volume":"24","author":"Kanzawa","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1011140818150_bb0105","first-page":"91S","article-title":"An integrated system for monitoring, reporting and analyzing phase I oncology clinical trials","volume":"20","author":"Atherton Skaff","year":"1999","journal-title":"Controll Clin Trials"},{"key":"10.1023\/A:1011140818150_bb0110","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/00003495-199754030-00009","article-title":"Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer","volume":"54","author":"Noble","year":"1997","journal-title":"Drugs"},{"key":"10.1023\/A:1011140818150_bb0115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/bjc.1998.750","article-title":"The role of gemcitabine in the treatment of other tumours","volume":"78","author":"Carmichael","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1023\/A:1011140818150_bb0120","first-page":"58","article-title":"Phase I study of CPT-11 and gemcitabine in patients with solid tumors","volume":"2","author":"Lima","year":"1999","journal-title":"Cancer Ther"},{"key":"10.1023\/A:1011140818150_bb0125","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1200\/JCO.1997.15.3.921","article-title":"Phase I \u2013 11 study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer","volume":"15","author":"Shirao","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011140818150_bb0130","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.1998.16.12.3858","article-title":"Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors","volume":"16","author":"Saltz","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011140818150_bb0135","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1200\/JCO.1996.14.5.1656","article-title":"Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer. Usefulness of mathematic modeling to determine maximum-tolerable dose","volume":"14","author":"Shepherd","year":"1996","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419541151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419541151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/12\/5\/627\/19479214\/12-5-627.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:03:59Z","timestamp":1582182239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419541151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["S0923753419541151"],"URL":"https:\/\/doi.org\/10.1023\/a:1011140818150","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2001,5]]}}}